CONCLUSIONS: The translation evidence tracking tool is a unique device enabling researchers to submit a consistent and comprehensive translation dossier for FDA review.

PRM129
FINAL REPORTS FOR TRANSLATION AND LINGUISTIC VALIDATION OF CLINICAL OUTCOME ASSESSMENTS
Zarafkhani B1, Chulis C2, Simon M3
1TransPerfect, Research Triangle Park, NC, USA; 2TransPerfect, New York, NY, USA; 3TransPerfect, Paris, France

OBJECTIVES: As the use of existing translated clinical outcome assessments (COAs) across studies is common and continues to increase, appropriate documentation of their translation and linguistic validation processes utilized to create target language versions is essential. METHODS: A review of the contents of final reports and certifications for previously completed COA translations was conducted. Additional discussions with sponsors and CROs regarding final reports, and the prevalence of sponsor requirements for language versions were analyzed. Additionally, linguists provided their feedback on translatability of responses and agreement level with statements about treatment or condition.

RESULTS: Final reports for linguistic validation are not provided consistently across the industry. While some companies provide a final report for every project, upon further discussion with sponsors within the industry it was revealed that some companies do not automatically generate reports or provide them to sponsors upon completion of the linguistic validation process. Based upon regulatory expectations for review of translated COAs, it is recommended to utilize a final report which summarizes the overall linguistic validation project. This report should document the process used in detail, the reasoning for linguistic decisions at each stage, evidence of creative interviewing, cognitive interviewing population, demographic information of the respondents, a summary of the findings, the final formatted version of the questionnaire, and the relevant certification.

CONCLUSIONS: Final reports for COA language versions provide valuable information needed to make critical decisions regarding the use of existing translations. Linguistic validation reports should be structured as complete packages addressing each item regulatory authorities require for review of translations, so the sponsor may easily include this in their submission packages. Final reports should include every COA language version to document the translation and linguistic validation process completed.

PRM130
TRANSLATABILITY OF RESPONSE SETS USED IN PATIENT REPORTED OUTCOMES AND BEST PRACTICES FOR DEVELOPMENT
Glawich M1, McKerns S2, Talbert M3, Brandt BA4
1Corporate Translations, Inc.; 2East Hartford, CT, USA; 3Corporate Translations, Inc.; 4Chicago, IL, USA

OBJECTIVES: To determine the best response sets for use in Patient Reported Outcomes (PRO) instruments intended for translation and subsequent data collection in multinational clinical trials, and to make recommendations for response options to avoid. As sound response sets are essential for data collection, a high degree of translatable is vital.

METHODS: Twelve response sets from previously translated PRO instruments were analyzed. Additionally, linguists provided their feedback on translatability of the response sets. Observed response sets included measures of patient treatment satisfaction, improvement, discomfort level, frequency of symptoms or adverse affects and agreement level with statements about treatment or condition.

RESULTS: A response set constructed of "Strongly agree, agree, uncertain, disagree, strongly disagree" was conceptually equivalent to "Agree" in 94% of observed back-translations. In comparison, response options including the phrase "...of the time" were conceptually equivalent in 42% of back-translations. The concept of "fair" was conceptually equivalent in 64% of back-translations and was found to strongly disagree was conceptually equivalent to the source in 94% of observed back-translations. The results of translatability checks are compiled and discussed with the developer of the measure, which is then adapted in accordance with these findings. The results of translatability checks are recommended to utilize a final report which summarizes the overall linguistic validation process conducted. This step helps identify potential issues and develop solutions that side-step potential problems in the later translation process. The aim of this study was to assess the nature of issues that translatability highlights.

CONCLUSIONS: Translatability is assessed by native speakers representing several language groups (e.g. Europe, Africa, Asia, and Latin America). The linguists are asked to identify possible grammatical, lexical and cultural issues. Their recommendations are compiled and discussed with the developer of the measure, which is then adapted in accordance with these findings. The results of translatability checks are reviewed to find common issues that the process illuminates.

PRM131
HOW MIGHT EXPERIENCE-BASED UTILITY MEASURES INFLUENCE REIMBURSEMENT DECISIONS?
Marsh E1, Brown M2
1United BioSource Corporation, London, UK; 2United Kingdom

OBJECTIVES: The measurement of the 'quality' part of the QALY used to assess health-related quality of life (HRQL) conventionally based upon the general publics' preferences for different health states. Research from behavioural economics tells us that the elicitation of preferences to inform this analysis introduces a number of biases into the estimation of the utility generated by technologies. In response to this, various authors have considered the theoretical possibility of replacing the preference-based approaches with experience-based estimates of health related utility gains. This paper compares the ICERs for a range of interventions estimated based on both preference-based and experience-based valuation techniques.

METHODS: Tariffs associated with changes in health states were extracted from published data. Tariffs based on four methods were identified: TTO, standard gamble, life satisfaction, and day affect. These data were combined with estimates of the cost and effect of a range of interventions to model the impact on ICERs of these alternative tariffs, how this varied with intervention type and tariff method, and the challenges in adopting alternative tariffs.

RESULTS: Experience-based tariffs generate lower ICERs for interventions that generated improvements in the social and mental dimensions of health outcomes, and higher ICERS for those that target the pain dimensions of health outcomes. This trend is not, however, replicated for different experience-based alternative tariffs. Results: Experience-based utility represents an alternative to the preference-based utility measures conventionally employed within health economics. If optimal use is to be made of health care budgets, further work is required to understand why different utility measures produce different ICERs, and further debate is required to inform the appropriate basis for reimbursement decisions.

PRM132
USING CLINICAL OUTCOME ASSESSMENTS AND ECONOMIC DATA TO FACILITATE PATIENT ACCESS IN RHEUMATOID ARTHRITIS
Gater A1, Kitchen H2, Honon L3, Hansen B4, Højbjerg L5, Strandberg-Larsen M6
1Whirligig Values, Rollington, Cheshire, UK; 2Nord Nordisk A/S, Copenhagen, Denmark

OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease, affecting over 2.9 million adults in Europe. A challenge for new RA therapies is demonstrating added value not only in efficacy and tolerability but also in terms of overall benefit for patients, carers, health care systems and society. The aims of this study were to document current unmet needs in RA in terms of patient-reported and economic burden and how such concepts may be assessed to capture the value of RA treatments.

METHODS: Articles were identified via searches in MEDLINE, EMBASE, EMBASE, CRD databases and PSYCINFO using pre-defined search terms and limits. PRO measures were identified via the reviewed literature and the Patient-Reported Outcome and Quality of Life Database (PROQOLI) and were assessed in context of FDA guidelines.

RESULTS: The literature search revealed 2,517 studies of which 123 articles were reviewed in full. RA symptoms significantly impact patient’s physical functioning, daily activities, and ability to work. Financial stability of patients and caregivers is affected and direct and indirect costs are incurred by health care systems. A conceptual model summarising patient-reported economic burden of RA was developed to identify key measurement concepts which can demonstrate efficacy, tolerability, and wider impact of RA treatments. Relevant endpoint measures were identified; beyond traditional symptom reports the assessment of health-related quality of life, sleep, fatigue, daily activities, resource use and work productivity can provide data for regulatory, reimbursement decision-making, and patient decision-making. The patient-focused approach is increasingly advocated for underpinning individual and societal health care decisions. PRO measures, therefore, are essential for monitoring treatment outcomes among RA patients both in clinical trials and clinical practice. Where appropriate the use of numerical rating scales in clinical trials there exists opportunity to demonstrate the overall efficacy, tolerability, and value of a treatment to key stakeholders including regulatory and HTA bodies.

PRM133
REVIEWING TRANSLATABILITY PRIOR TO TRANSLATION AND LINGUISTIC VALIDATION OF PROS
Gordon-Stables R1, Wild D2
1Adelphi Values, Bollington, Cheshire, UK; 2Adelphi Values, Bollington, Cheshire, UK

OBJECTIVES: To assess the nature of issues that translatability highlights.

METHODS: When developing a new PRO for use in multinational studies it is recommended to utilize a final report which summarizes the overall linguistic validation process conducted. This report should document the process used in detail, the reasoning for linguistic decisions at each stage, evidence of creative interviewing, cognitive interviewing population, demographic information of the respondents, a summary of the findings, the final formatted version of the questionnaire, and the relevant certification.

RESULTS: A review of the contents of final reports and recommendations for response options to avoid. As sound response sets are essential for data collection, a high degree of translatable is vital.

CONCLUSIONS: Translatability assessments in context of FDA guidelines are recommended.

PRM134
REGRESSION METHODS FOR HEALTH-RELATED QUALITY OF LIFE DATA IN LONGITUDINAL SETTINGS: ARE MORE ADVANCED TECHNIQUES REALLY PERFORMING BETTER?
Hoehler M1, Dingel A, Hölle R2
1Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany

OBJECTIVES: The statistical analysis of health utilities and health-related quality of life (HRQL) scores poses various challenges due to the distributional properties such data commonly exhibit. These include skewness and heteroscedasticity.